TKPHF
Takeda Pharmaceutical Company Limited
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
36.44
■ 0.00 (0.00%)
MARKET · —
Price
Open
36.44
Prev close
36.44
Day high
34.00
Day low
34.00
Volume
100
Market cap
$58.19B
P/E (TTM)
—
52W range
26.33 – 39.20
Trailing performance
Returnvs SPY
1W
+8.68%
+10.0%
1M
+16.83%
+13.1%
3M
+11.78%
+8.7%
6M
-1.51%
-12.6%
YTD
+18.20%
+5.9%
1Y
+23.74%
+3.7%
3Y
+22.28%
-51.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$58.19B
Enterprise value$5.13T
Revenue (TTM)$4.62T
Gross profit$2.98T
EBITDA$1.25T
Net income$-163.44B
EPS (TTM)$-0.66
Free cash flow$541.44B
Total cash$460.98B
Total debt$5.54T
Book value / share$29.97
Shares outstanding1.60B
Float1.58B
Short % of float—
Dividend yield3.56%
Beta (5Y)0.10
Valuation & profitability ratios
Trailing P/E—
Forward P/E44.99
PEG ratio0.41
Price / sales—
Price / book1.22
EV / revenue1.11
EV / EBITDA4.11
Gross margin64.47%
Operating margin16.45%
Profit margin-3.54%
Return on equity-2.26%
Return on assets2.69%
Debt / equity73.25
Current ratio1.14
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Total revenue | $4.51T | $580.36B | $4.26T | $632.14B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $191.80B | $152.82B | $338.87B | $317.02B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net income | $191.80B | $152.82B | $338.87B | $317.02B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $1.16T | +4.3% |
| Next quarter | — | — | $1.21T | +1.9% |
| Current year | — | — | $4.69T | +692.1% |
| Next year | — | — | $4.77T | +1.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.03%
Held by institutions50.24%
Institutions holding465
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
521.50K
Total on file
Moving averages & technicals
SMA 10
34.59
+5.35% from price
SMA 20
34.67
+5.09% from price
SMA 50
33.40
+9.09% from price
SMA 100
33.14
+9.96% from price
SMA 200
32.50
+12.11% from price
EMA 12
34.90
+4.40% from price
EMA 26
34.42
+5.86% from price
EMA 50
33.85
+7.65% from price
RSI (14)
61.2
Neutral
MACD (12,26,9)
0.48
Hist 0.06
ATR (14)
0.93
2.56% of price
Realised vol 30D
60.1%
Annualised
Bollinger upper
37.79
20, 2σ
Bollinger lower
31.56
20, 2σ
50 / 200 cross
Golden
33.40 vs 32.50
Trend bias
Above 200
+12.11%
Risk profile
Beta vs SPY
-0.05
Less volatile than market
Correlation to SPY
-0.01
Largely independent
Realised vol 30D
60.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-24.9%
Peak to trough
Max drawdown 5Y
-29.6%
Peak to trough
ATR 14
0.93
2.56% of price
Beta (reported)
0.10
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Takeda (TSE:4502) Stock Looks Undervalued As AI Drug Discovery Progress Builds
Simply Wall St. · 1d ago
Ascentage Pharma Group International H1 Earnings Call Highlights
MarketBeat · 2d ago
Asian Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading
MT Newswires · 4d ago
Wall Street Analysts Think Takeda Pharmaceutical Co. (TAK) Could Surge 26.41%: Read This Before Placing a Bet
Zacks · 4d ago
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
GlobeNewswire · 4d ago
WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO
PR Newswire · 5d ago
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Zacks · 5d ago
Best Income Stocks to Buy for August 17th
Zacks · 5d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.